HIF1A and pancreatic neoplasm: These inhibitors not only sensitize pancreatic cancer cells to gemcitabine, a standard chemotherapeutic agent, but also demonstrate potent anti-angiogenic effects by suppressing key angiogenesis and hypoxia-related proteins, such as VEGF and HIF-1α, thereby inhibiting endothelial cell migration and tube formation.